Announcements Trials

Browse Landscape

Phase

Status

Completed 4 Terminated 2 Withdrawn 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Transitional Cell Cancer of Renal Pelvis and Ureter 1

Interventions

pembrolizumab 562 Specimen Handling 490 Carboplatin 451 Magnetic Resonance Spectroscopy 444 Cyclophosphamide 418 Cisplatin 406 Radiotherapy 353 Gemcitabine 314 Bevacizumab 313 Paclitaxel 298 Biopsy 290 Drug Therapy 283 Blood Specimen Collection 248 Capecitabine 245 Oxaliplatin 241 fludarabine 240 Nivolumab 234 venetoclax 221 Injections 213 Docetaxel 211 Fluorouracil 205 Dexamethasone 187 Radiosurgery 182 Rituximab 159 Standard of Care 158 Pemetrexed 156 Surgical Procedures, Operative 148 durvalumab 145 atezolizumab 145 Leucovorin 139

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × padeliporfin × Clear all

NCT04620239 2026-02-04

UCM301

Steba Biotech S.A.

Phase 3 Recruiting

Transitional Cell Cancer of Renal Pelvis and Ureter

Data powered by HemOnc (CC BY 4.0) Colophon ⚡